UCLA researchers from the Department of Medicine have discovered a novel therapeutic target (between the interaction of the heart and liver) to treat heart failure with preserved ejection fraction (HFpEF), which afflicts approximately half of all patients with heart failure.
Contact UCLA Technology Development Group for more information.
Related papers (from the inventors only):
Cao Y, Lusis AJ. Coagulation factor with potential for the treatment of heart failure. Clin Transl Med. 2022;12:e1144. 10.1002/ctm2.1144
Keywords: Heart failure, heart failure with preserved ejection fraction (HFpEF), cardiovascular disease, liver, FXI, metabolic disease